Periprocedural myonecrosis or infarction are associated with short, intermediate, and long term adverse outcomes. Previous study indicated 12.6% of patients suffered a peri-procedural CK-MB rise by overlapping use of drug-eluting stents for long coronary lesions. Here the investigators hypothesize that peri-procedural use of tirofiban could reduce the occurrence of periprocedural infarciton in elective patients with long coronary lesions treated by overlapping use of drug-eluting stents.
According to the results of 12.6% occurrence of peri-procedural myocardial infarction after long stent implantation by previous report\[International Journal of Cardiology 2009;134: 231-237\], the investigator hypothesize the 50% reduction of peri-procedural MI by using tirofiban. Three hundred and sixty-nine patients in each group are needed to reach 80% of power with α 0.05.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
748
10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
same use as tirofiban
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
periprocedural infarction
definition of periprocedural MI is a CK elevation \>3 times the upper limit of normal.
Time frame: 12h after procedure
major bleeding
The safety outcome of major bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) definition
Time frame: during hospitalization (up to 2 weeks)
major adverse cardiac event
major adverse cardiac event (MACE) includes cardiac death, target vessel revascularization, and re-occurrence of myocardial infarction after discharge
Time frame: one year after procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.